Brought to you by 
RDO nets $56.4mm for Pharmacyclics
11 Mar 2013
Executive Summary
Pharmacyclics Inc. (developing treatments for cancer and immune-mediated diseases) netted $56.4mm through the registered direct offering of 6.45mm common shares at $8.85 each (a 10% premium). The company's CEO bought 678k of the stock.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Private Investment in Public Equity
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
RDO nets $56.4mm for Pharmacyclics
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice